Repligen | RGEN - Sales Revenues

Repligen reported $155.74M in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
Agilent USD 1.66B 30M Dec/2023
Align Technology USD 997.4M 40.67M Mar/2024
Bio Techne USD 272.6M 4.34M Dec/2023
BioMarin Pharmaceutical USD 649M 2.79M Mar/2024
Bristol-Myers Squibb USD 11.9B 423M Mar/2024
Bruker USD 854.5M 111.7M Dec/2023
Catalent USD 1.02B 42M Dec/2023
Charles River Laboratories USD 1.01B 13.15M Dec/2023
Danaher USD 5.8B 605M Mar/2024
Dentsply International USD 1.01B 65M Dec/2023
Exact Sciences USD 646.88M 18.55M Dec/2023
General Electric USD 16.1B 3.32B Mar/2024
Henry Schein USD 3.02B 145M Dec/2023
Illumina USD 1.12B 3M Dec/2023
IQVIA Holdings USD 3.87B 132M Dec/2023
Mettler Toledo International USD 934.99M 7.47M Dec/2023
Myriad Genetics USD 196.6M 4.7M Dec/2023
Patterson Companies USD 1.62B 36.68M Dec/2023
Pfizer USD 14.25B 1.02B Dec/2023
Repligen USD 155.74M 14.55M Dec/2023
Revvity USD 695.9M 25.16M Dec/2023
Standard Biotools USD 28.19M 2.82M Dec/2023
Thermo Fisher Scientific USD 10.34B 546M Mar/2024
Waters USD 819.47M 107.78M Dec/2023
West Pharmaceutical Services USD 695.4M 36.6M Mar/2024